What do systematic reviews say?

Telephone‐based disease monitoring vs face‐to‐face monitoring

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Very low

Telephone‐based disease monitoring vs face‐to‐face monitoring

It is very uncertain whether telephone‐based disease monitoring changes flare‐ups/relapse (dichotomous; adults) compared with face‐to‐face monitoring (very low certainty).

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.17 [0.47, 2.89]
  1 study · 42 participants
  Very low

Telephone‐based disease monitoring vs face‐to‐face monitoring

It is very uncertain whether telephone‐based disease monitoring changes flare‐ups/relapse (dichotomous; children) compared with face‐to‐face monitoring (very low certainty).

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 0.24 [0.03, 2.05]
  1 study · 86 participants
  Very low

Telephone‐based disease monitoring vs face‐to‐face monitoring

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 123 participants
  Very low

Telephone‐based disease monitoring vs face‐to‐face monitoring

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 86 participants
  Very low